Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Oct 19, 2020 9:55 AM - Oct 20, 2020 5:30 PM

(Eastern Standard Time)

Fort Washington, PA 19034

DIA Annual Canadian Meeting

Session 3 Track B: Enhancing Patient Access Through the Access Continuum: Update and New Initiatives

Session Chair(s)

Samar  Darwish, MBA, MSc

Samar Darwish, MBA, MSc

Director, Drug Regulatory Affairs

Boehringer Ingelheim, Canada

The four main steps of the access continuum start with Drug Development, HC regulatory review, HTA funding recommendation, and Provincial purchasing review and price negotiations. The time from HC granting of marketing authorization (MA) to drug plan coverage within the pan-Canadian Pharmaceutical Alliance (pCPA) process could take between 8 months to more than 2 years, and the HC-HTA alignment initiative was implemented in 2018 to minimize the time between HC MA and HTA recommendations. Its provision for voluntary opt-in by industry members to allow sharing of information has the potential to shorten the timeframe for HTA decision after HC approval by 180 days and would have an even bigger impact (~3-6 month saving) if the HTA decision could be issued at the same time as HC decision. This session will provide an update on this initiative from the HC, HTA and Industry perspective, as well as industry initiatives to introduce efficiency and predictability in the pCPA process.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Discuss the different elements affecting patient access to new drugs
  • Describe benefits and challenges for HTA/HC aligned reviews
  • Debate approaches to introduci efficiency and predictability in the pCPA process

Speaker(s)

Emile  Geoffroy, MS

Aligned reviews HC Experiences

Emile Geoffroy, MS

Health Canada, Canada

Manager, Plannng, Performance and Stakeholder Engagement Division

Trevor  Richter, PhD

Aligned reviews HTA Experiences

Trevor Richter, PhD

CADTH, Canada

Director of Pharmaceutical Reviews

Mandy  Collier

Speaker

Mandy Collier

Health Canada, Canada

Director, Health Products and Food Branch

Joe  Farago

Drug Access and Re-imbursement pCPA related initiatives

Joe Farago

Innovative Medicines Canada, Canada

Executive Director Private Markets and Innovation

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.